The evolution of ophthalmic surgeries, in general, has resulted in procedures that are as safe as and less time-consuming than the original surgeries requiring suture placement, and, importantly, with outcomes that are enhanced.
April 15 marked the 10-year anniversary of FDA approval of onabotulinumtoxinA (Botox Cosmetic, Allergan) to help improve the look of moderate to severe frown lines between the eyebrows in patients aged 18 to 65 years.
Diseases of the canaliculus can be managed with microtrephination and the silicone stent.
Preparing the contracted socket for grafting requires careful assessment and planning to ensure a positive result.
Numerous small-incision approaches make it possible to gain access to orbital tumors. The choice of surgical approach or combination of approaches is dictated by the size and location of the lesion or the area being pursued.
Las Vegas—The use of a femtosecond laser (IntraLase, Advanced Medical Optics) to create channels for placement of corneal implants (Intacs, Addition Technology Inc.) seems to provide better visual and refractive improvements compared with mechanical implantation of the segments, according to Aylin Ertan, MD.
London—The visual outcomes of patients with keratoconus were improved when using a femtosecond laser (IntraLase, Advanced Medical Optics Inc.) to create the channels for implantation of intrastromal corneal implants (Intacs, Addition Technology Inc.), according to Sheraz Daya, MD, FACS.
Irvine, CA—Visiogen Inc. has received FDA approval to expand the phase III clinical trial of its dual-optic accommodating IOL (Synchrony) in the United States.
Las Vegas—Refractive lens exchange (RLE) is associated with an increased burden of informed consent disclosure because of the complex issues, both current and future, accompanying that procedure, said Douglas D. Koch, MD, at the Refractive Sur-gery Subspecialty Day during the American Academy of Ophthalmology annual meeting.
Las Vegas—Selective laser trabeculoplasty (SLT) is comparable to medical treatment as the initial therapy for open-angle glaucoma (OAG) or ocular hypertension, according to results of a study reported by L. Jay Katz, MD, and colleagues here at the American Academy of Ophthalmology annual meeting.